Extract: An investigation of the bradykinin system in cystic fibrosis of the pancreas was undertaken because of the potential role of bradykinin in the function of glandular tissues and in the ...
Blood–brain barrier (BBB) disruption and transendothelial trafficking of immune cells into the central nervous system (CNS) are pathophysiological hallmarks of neuroinflammatory disorders like ...
THE plasma kinins are vasoactive polypeptides deriveoteins. Plasma kinin-forming enzyme, named kallikrein, produces plasma kinins when incubated with plasma or fractionated globulin. Trypsin and ...
Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...
Recently published real-world data with Firazyr (icatibant), the selective B2 bradykinin receptor antagonist from Takeda Pharmaceutical Co. Ltd. to treat acute hereditary angioedema (HAE) attacks, ...
Intellia’s multi-national Phase 1/2 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I or Type II hereditary angioedema (HAE). This ...
Dr. Schmaier’s major investigative work is on the vascular biology of the plasma kallikrein/kinin (KKS) and rennin angiotensin (RAS) systems. The Schmaier laboratory recognized that the endothelial ...
This is something new; although there are other companies targeting just one indication, I have not recently come across one with multiple molecules targeting just one indication. On closer look, ...
Angioedema and urticaria often constitute a challenge in daily clinical practice. They may either co-occur or present as independent conditions. They are characterized by a complex pathomechanism, and ...
KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback